louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06086782: Effects of Autogenic and Reciprocal Inhibition on Trapezitis
Official title: Comparative Effects of Autogenic and Reciprocal Inhibition Techniques on Pain, Disability and Range of Motion Among Smart Phone User With Trapezitis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Neck Pain
Keywords: trapezitis
Disability
neck pain
Lead sponsor: Riphah International University
Sponsor class: OTHER
First posted: 2023-10-17
Enrollment: 42
Sex: ALL
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Aim of my study is to compare two techniques of METS i.e., autogenic and reciprocal inhibition techniques on pain, disability and Range of motion among smart phone user with trapezitis.

Detailed description: Study focuses trapezitis in smart phone users. There are many different causes of neck pain, but one common factor is upper trapezitis. This refers to pain and spasms in the neck caused by inflammation of the trapezius muscle. The aim of this study is to compare the effects of autogenic and reciprocal inhibition techniques on pain, range of motion and disability among smart phone user with trapezitis.

This study will be randomized clinical trial and 40 patients male and female with age 20 to 40 years having NPRS \>3 according to inclusion criteria will be included in the study. They will be allocated into 2 groups by non-probability convenience sampling technique. Group A will receive autogenic inhibition technique with conventional physical therapy while Group B will receive reciprocal inhibition technique with conventional therapy. Outcome measures; Neck Disability Index, goniometry and Numeric Pain Rating Scale will measure neck function and neck pain intensity. Total 12 sessions, 3 sessions per week for 4 weeks were provided. Each session was 45 minutes long and measurements will be taken at the baseline and at the end of 4th week. Data will be analyzed by SPSS version 25

Eligibility criteria: Inclusion Criteria:

* Mobile phone users age between 20 -40 years old.
* Both gender male and female included.
* Neck pain (Numeric Pain Rating Scale \>3)
* With limited Neck ROMs.
* NDI scoring 15-24points (30-48%) moderate disability

Exclusion Criteria:

* Neck pain with whiplash or headache, neurological disorder.
* History of previous head, neck, cervical spine or shoulder surgery.
* Infection or inflammatory arthritis in the cervical spine.
* Trigger point of Upper trapezius will be excluded.
* History of cervical radiculopathy.
* Diagnosed fibromyalgia and myopathy.
* History of cancer.

Primary outcomes:
measure: Goniometry
timeFrame: 4 weeks
Secondary outcomes:
measure: NPRS (numeric pain rating scale)
timeFrame: 4 weeks
measure: NDI (neck disability index)
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Lahore
country: Pakistan
facility: Nusrat Rashid Medical Complex
state: Punjab
Study officials:
affiliation: Riphah International University
name: Humera Mubashar, MS
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04989582: Effectiveness of a Nursing Intervention for Nurses Have Experienced Trauma: a Study Based on Swanson's Caring Theory
Official title: Effectiveness of a Nursing Intervention for Nurses Have Experienced Trauma: a Study Based on Swanson's Caring Theory
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Nurses Who Have Experienced Trauma
Lead sponsor: Yonsei University
Sponsor class: OTHER
First posted: 2021-08-04
Enrollment: 112
Sex: ALL
Minimum age (years): 23
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: This study aimed to (1) develop an internet-based psychiatric nursing intervention, based on Swanson's theory of caring, and (2) examine its effects on functional health, resilience, social support, post-traumatic stress, depression, and anxiety.

This study was a randomized clinical trial(RCT) study with repeated measures to identify the effectiveness of an internet-based psychiatric nursing intervention. Participants were evaluated at the following time points: pre-test (pre), post-test (post-test 1, immediately after intervention), and follow-up (post-test 2, one month after the intervention) to assess the sustainability of the internet-based psychiatric nursing intervention.

Of the 112 women who enrolled in the study, 10 dropped out before post-test 1, resulting in 102 participants who completed all interventions and surveys.


Eligibility criteria: Inclusion Criteria:

1. nurse aged from 23 to 40 years
2. a PTS score of 64 or lower on the PTSD checklist for DSM-5 (PCL-5) developed by Weathers et al., revised by Weathers et al., and translated into Korean by Kim et al.,
3. nurse who can access the program through a computer or mobile
4. nurse who understand the purpose of the research and voluntarily agree to participate in the research.

Exclusion Criteria:

1. presence of psychiatric conditions with hallucinations and delusions
2. diagnosis of an intellectual disability that would make understanding the intervention procedure difficult. Although a standard cut-off was not present in the PCL-5, women who exceeded 80% (64 points) of the total score were excluded to rule out high-risk women with severe trauma.

Primary outcomes:
measure: functional health
timeFrame: one month after the intervention
measure: resilience
timeFrame: one month after the intervention
measure: social support
timeFrame: one month after the intervention
measure: post-traumatic stress
timeFrame: one month after the intervention
measure: depression
timeFrame: one month after the intervention
measure: anxiety
timeFrame: one month after the intervention
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Yonsei University College of Nursing
Study officials:
References:
Clinical trial NCT06440382: Scottish Cervical Screening and Ethnicity Project
Official title: Scottish Cervical Screening and Ethnicity Project
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cervical Cancer
Lead sponsor: University of Edinburgh
Sponsor class: OTHER
First posted: 2024-06-03
Enrollment: 600000
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_CONTROL
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: women (aged 20 to 70) who were living in Scotland in April 2011 and took part in the 2011 Scottish census, and who were invited to participate in the Scottish Cervical Screening Programme between January 2012 and December 2018

Brief summary: To identify important ethnic inequalities in cervical cancer screening participation in Scotland, and explore possible reasons for these.

Detailed description: The 2011 Census database was linked, via the Community Health Index number, with the Scottish Cervical Screening Programme data to generate anonymised individual level information on cervical screening participation rates by self-reported ethnic group in Scotland. The cohort comprised women (aged 20 to 70) who were living in Scotland in April 2011 and took part in the 2011 Scottish census, and who were invited to participate in the Scottish Cervical Screening Programme between January 2012 and December 2018. All ethnic groups were compared to the population of White Scottish women. Qualitative interviews were carried out with 50 women (South Asian, East European, Chinese, Black African / Caribbean, or White Scottish).

Eligibility criteria: Inclusion Criteria:

* screening invitees through national programme

Exclusion Criteria:

* not invited to cervical screening

Primary outcomes:
measure: % women who attend cervical screening
timeFrame: within 6 months of date of invitation
Secondary outcomes:
Other outcomes:
Locations:
city: Edinburgh
country: United Kingdom
facility: University of Edinburgh
Study officials:
References:
Clinical trial NCT03066882: Dietary Effects on Weight Loss and Lipid Profile in Sedentary Women
Official title: Comparison Effects of Negative Calorie Diet and Low-calorie Diet on Weight Loss and Lipid Profile in Sedentary Overweight/Obese Middle-aged and Older Women
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Obesity
Overweight
Life Style
Keywords: Caloric Restriction
Diet
Obesity
Overweight
Sedentary Lifestyle
Weight loss
Women
Lead sponsor: P.L.Shupik National Medical Academy of Post-Graduate Education
Sponsor class: OTHER
First posted: 2017-03-01
Enrollment: 37
Sex: FEMALE
Minimum age (years): 45
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: SUPPORTIVE_CARE

Brief summary: Negative-calorie diet is among the popular dieting guides for weight loss; however, there is still little knowledge about this method. The present study aimed to determine the effects of negative-calorie diet on weight loss and lipid profile, and to compare its efficiency with low-calorie diet.


Eligibility criteria: Inclusion Criteria:

* Non-smokers and weight-stable (± 2 kg, for more than one year) with no history of regular exercise in at least three months before the study.

Exclusion Criteria:

* History of CVD and other disorders such as diabetes, depression, eating disorders, chronic medications, kidney disease, cancer, food allergies or intolerances to items used in meals.
* Subjects with abnormality in thyroid or Electrocardiograph, any history of anti-obesity medication or weight loss drugs or dietary supplementations for weight control.

Primary outcomes:
measure: Weight
timeFrame: pre-study
measure: Total cholesterol (Total-C)
timeFrame: pre-study
measure: High-density lipoprotein -cholesterol (HDL-C)
timeFrame: pre-study
measure: Low-density lipoprotein -cholesterol (LDL-C)
timeFrame: pre-study
measure: Triglycerides (TG)
timeFrame: pre-study
Secondary outcomes:
measure: Weight
timeFrame: 3-month
measure: Total cholesterol (Total-C)
timeFrame: 3-month
measure: High-density lipoprotein -cholesterol (HDL-C)
timeFrame: 3-month
measure: Low-density lipoprotein -cholesterol (LDL-C)
timeFrame: 3-month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT02510482: Biological Variation of Cardiac Biomarkers in Aortic Valve Stenosis
Official title: Biological Variation of Cardiac Biomarkers in Aortic Valve Stenosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Aortic Valve Stenosis
Keywords: cardiac biomarkers
Lead sponsor: Maastricht University Medical Center
Sponsor class: OTHER
First posted: 2015-07-29
Enrollment: 25
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Individuals with clinically stable moderate aortic valve stenosis

Brief summary: Calcified aortic valve stenosis (CAVS) is a progressive disease and nowadays, the cornerstone in diagnostics and follow-up is echocardiography. Cardiac biomarkers (such as cardiac troponins T and I and NT-pro-BNP) hold promise to fulfil a role in early recognition of complications concerning the aortic valve and decompensation. For this purpose, it is important to assess the normal biological variation (BV) of cardiac biomarkers in CAVS. The assessment of biological variation will contribute to a better understanding of fluctuation of cardiac biomarkers in subjects with stable CAVS. These data will improve monitoring of CAVS using cardiac biomarkers.


Eligibility criteria: Inclusion Criteria:

* Clinically stable moderate aortic valve stenosis
* No evidence of acute cardiovascular disease

Exclusion Criteria:

* Acute myocardial infarction in the last six months
* Pulmonary embolism in the last six months
* Hospitalisation for heart failure in the last six months
* Chronic kidney disease

Primary outcomes:
measure: Cardiac troponin T
timeFrame: One year
measure: Cardiac troponin I
timeFrame: One year
measure: NT-pro-BNP
timeFrame: One year
Secondary outcomes:
Other outcomes:
Locations:
city: Maastricht
country: Netherlands
facility: Maastricht University Medical Center
Study officials:
References:
citation: Klinkenberg LJ, van Dijk JW, Tan FE, van Loon LJ, van Dieijen-Visser MP, Meex SJ. Circulating cardiac troponin T exhibits a diurnal rhythm. J Am Coll Cardiol. 2014 May 6;63(17):1788-95. doi: 10.1016/j.jacc.2014.01.040. Epub 2014 Feb 26.
citation: Peeters FECM, Kietselaer BLJH, Hilderink J, van der Linden N, Niens M, Crijns HJGM, Meex SJR. Biological variation of cardiac markers in patients with aortic valve stenosis. Open Heart. 2019 May 8;6(1):e001040. doi: 10.1136/openhrt-2019-001040. eCollection 2019.
Clinical trial NCT04886882: Topical Agents Containing Magnesium Sulfate & Wound Healing in the Rat Model
Official title: The Effect of Topical Agents in Cream Formations Containing Magnesium Sulfate on Wound Healing in the Rat Model
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: EARLY_PHASE1
Conditions: Wound Heal
Keywords: magnesium sulphate
wound healing rat model
hydroxyproline
Lead sponsor: Başakşehir Çam & Sakura City Hospital
Sponsor class: OTHER_GOV
Collaborators: name: Istanbul Kent University
First posted: 2021-05-14
Enrollment: 30
Sex: FEMALE
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: An experimental study examining wound healing in 5 different groups on 30 rats.

Detailed description: Magnesium topically increases collagen synthesis and angiogenesis, providing faster and higher quality wound healing. In addition, with its analgesic effect, it will also eliminate the pain sensation caused by the wound and increase the quality of life of the patient whose skin integrity is impaired.

Eligibility criteria: Inclusion Criteria:

* healthy rats between ages of 8- 12 weeks

Exclusion Criteria:

* weight loss of more than 15% of body weight

Primary outcomes:
measure: 7th day evaluation
timeFrame: 7th day
Secondary outcomes:
measure: 15th day evaluation
timeFrame: 15th day
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Başakşehir Çam Ve Sakura Hospital
Study officials:
References:
Clinical trial NCT02327182: Safety Study of MT-4666 in Subjects With Alzheimer's Disease
Official title: A Long-Term Safety Study of MT-4666 in Patients With Mild to Moderate Alzheimer's Disease (AD)
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Alzheimer's Disease
Keywords: MT-4666
α7 nicotinic acetylcholine receptor agonist
Alzheimer's Disease
Cognitive function
Dementia
Central Nervous System Agents
Lead sponsor: Mitsubishi Tanabe Pharma Corporation
Sponsor class: INDUSTRY
First posted: 2014-12-30
Enrollment: 117
Sex: ALL
Minimum age (years): 55
Maximum age (years): 85
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of this study is to evaluate the safety and efficacy of 2 fixed dose of MT-4666 administered once daily for 52 weeks with or without receiving a concomitant acetylcholinesterase inhibitors (AChEIs), in patients with mild to moderate Alzheimer's Disease (AD).


Eligibility criteria: Inclusion Criteria:

* Probable Alzheimer's disease consistent with the National Institute on Aging and the Alzheimer's Association Criteria for Diagnosis of Alzheimer's Disease (McKhann et al. 2011).
* MMSE score of ≥ 14 and ≤ 24 at the screening and ≥ 12 and ≤ 26 at the baseline.
* Modified Hachinski Ischemic Score (mHIS) ≤ 4 at the screening
* Appropriate caregiver available
* Subject living at home or in facilities who do not require continuous (24-hour) nursing care.

Exclusion Criteria:

* Diagnosis of any other disease which may cause dementia
* Diagnosis of major depressive disorder as defined by Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) within last five years
* History of or current diagnosis of any psychosis
* History of myocardial infarction or unstable angina within six months before screening
* History of cerebrovascular disorder within 18 months before screening
* complication of hepatic disorder or renal dysfunction

Primary outcomes:
measure: Safety of 2 fixed doses of EVP-6124 in subjects with Alzheimer's disease. Criteria for evaluation include: adverse events, clinical laboratory tests, vital signs, body weight, 12-lead ECG, Columbia Suicide Severity Rating Scale (C-SSRS)
timeFrame: Up to week 56
Secondary outcomes:
measure: Change in Mini Mental State Examination (MMSE)
timeFrame: baseline to Week 52
measure: Change in Neuropsychiatric Inventory (NPI) total score
timeFrame: baseline to Week 52
Other outcomes:
Locations:
city: Osaka
country: Japan
facility: Investigational site
state: Kansai
Study officials:
affiliation: Kagawa University School of Medicine
name: Yu Nakamura, M.D., Ph.D.
role: STUDY_DIRECTOR
affiliation: Mitsubishi Tanabe Pharma Corporation
name: Kazuoki Kondo, M.D.
role: STUDY_DIRECTOR
References:
Clinical trial NCT01356082: CNAP™ Monitor Study
Official title: Accuracy of the CNAP™ Monitor in Providing Beat-to-beat Non-invasive Blood Pressure Readings
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Cardiac Surgery
Spinal Surgery
Lead sponsor: Nationwide Children's Hospital
Sponsor class: OTHER
First posted: 2011-05-19
Enrollment: 46
Sex: ALL
Minimum age (years): 5
Maximum age (years): 18
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Surgery patients at Nationwide Children's Hospital receiving an arterial line.

Brief summary: A newly developed monitor for continuous non-invasive blood pressure monitoring (CNAP™ Monitor 500; CNSystems Medizintechnik AG, Graz, Austria) provides beat-to-beat BP readings and is non-invasive. To make sure that anaesthesiologist can rely on and make clinical decisions based on values provided by the CNAP™ monitor, to demonstrate its reliability we will test it during the perioperative care of children.


Eligibility criteria: Inclusion Criteria:

* Patients who will already be having an indwelling arterial cannula placed for their surgical procedure.

Exclusion Criteria:

* Patients with history of a peripheral neurologic or neuropathic disorder.
* Patients in whom an invasive arterial cannula cannot be placed.
* Patients with vascular implants at the sites of non-invasive blood pressure measurement (fingers and upper arm of the examined arm).
* Edematous patients.
* Patients who are less than 20 kg.

Primary outcomes:
measure: Blood pressure
timeFrame: 1 Day (day of surgery)
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Nationwide Children's Hospital
state: Ohio
Study officials:
References:
Clinical trial NCT04595682: Estradiol Effects on Alcohol Across the Menstrual Cycle
Official title: Estradiol Effects on Behavioral and Reward Sensitivity to Alcohol Across the Menstrual Cycle
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Alcohol Use, Unspecified
Keywords: estradiol
reward
menstrual
hormone
Lead sponsor: University of Kentucky
Sponsor class: OTHER
Collaborators: name: National Institute on Alcohol Abuse and Alcoholism (NIAAA)
First posted: 2020-10-20
Enrollment: 100
Sex: FEMALE
Minimum age (years): 21
Maximum age (years): 35
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: BASIC_SCIENCE

Brief summary: This study will provide the first rigorous integrative test of the hypothesis that rapid rises in estradiol (a female hormone) increase the rewarding and disinhibiting effects of alcohol and that such increased sensitivity correlates with increased alcohol use. Identification of the behavioral mechanisms by which estradiol surges can increase alcohol use would provide a critical advancement of neurobiological theory of alcohol abuse in women, an understudied area, as well as provide new directions for personalization of alcohol abuse treatment in women.

In this study, naturally-cycling women will be examined daily over their menstrual cycle using an integrative combination of daily ecological assessments of hormone fluctuations and alcohol use along with strategically-timed laboratory tests of their acute sensitivity to the rewarding and disinhibiting effects of a controlled dose of alcohol.


Eligibility criteria: Inclusion Criteria:

* female
* regular menstrual cycle
* consume alcohol at least once per week
* no history of drug or alcohol dependence

Exclusion Criteria:

* use of hormone-based medications
* irregular menstrual cycle
* current pregnancy
* primary sensorimotor handicap
* frank neurological disorder
* pervasive developmental disorder
* frank psychosis
* diagnosed intellectual disability
* medical condition contraindicating alcohol use
* substance abuse history (except nicotine)
* body mass index (BMI) 30 or above
* alcohol abstainer

Primary outcomes:
measure: Attentional Bias (Early Follicular Phase)
timeFrame: 1 day
measure: Attentional Bias (Late Follicular Phase)
timeFrame: 1 day
measure: Disinhibition (Early Follicular Phase)
timeFrame: 1 day
measure: Disinhibition (Late Follicular Phase)
timeFrame: 1 day
Secondary outcomes:
Other outcomes:
Locations:
city: Lexington
country: United States
facility: University Of Kentucky Psychology Research Lab
state: Kentucky
Study officials:
affiliation: University of Kentucky
name: Mark Fillmore, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: University of Kentucky
name: Michelle Martel, PhD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Griffith AK, Martel MM, Eisenlohr-Moul T, Fillmore MT. Heightened sensitivity to the disinhibiting effect of alcohol in women during the late follicular phase of the menstrual cycle. Exp Clin Psychopharmacol. 2023 Aug;31(4):839-848. doi: 10.1037/pha0000611. Epub 2022 Oct 20.